{
    "componentChunkName": "component---src-templates-docs-js",
    "path": "/voorschrijven-en-follow-up/doac/overzicht",
    "result": {"data":{"site":{"siteMetadata":{"title":"LTA Antistollingszorg"}},"mdx":{"fields":{"id":"de093293-ceef-5200-8515-5de72ce93eee","title":"Overzicht","slug":"/voorschrijven-en-follow-up/doac/overzicht"},"body":"var _excluded = [\"components\"];\n\nfunction _extends() { _extends = Object.assign ? Object.assign.bind() : function (target) { for (var i = 1; i < arguments.length; i++) { var source = arguments[i]; for (var key in source) { if (Object.prototype.hasOwnProperty.call(source, key)) { target[key] = source[key]; } } } return target; }; return _extends.apply(this, arguments); }\n\nfunction _objectWithoutProperties(source, excluded) { if (source == null) return {}; var target = _objectWithoutPropertiesLoose(source, excluded); var key, i; if (Object.getOwnPropertySymbols) { var sourceSymbolKeys = Object.getOwnPropertySymbols(source); for (i = 0; i < sourceSymbolKeys.length; i++) { key = sourceSymbolKeys[i]; if (excluded.indexOf(key) >= 0) continue; if (!Object.prototype.propertyIsEnumerable.call(source, key)) continue; target[key] = source[key]; } } return target; }\n\nfunction _objectWithoutPropertiesLoose(source, excluded) { if (source == null) return {}; var target = {}; var sourceKeys = Object.keys(source); var key, i; for (i = 0; i < sourceKeys.length; i++) { key = sourceKeys[i]; if (excluded.indexOf(key) >= 0) continue; target[key] = source[key]; } return target; }\n\n/* @jsxRuntime classic */\n\n/* @jsx mdx */\nvar listDOAC = [{\n  title: \"apixaban\",\n  url: \"https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/a/apixaban\",\n  linkName: \"Farmaceutisch Kompas\"\n}, {\n  title: \"dabigatran\",\n  url: \"https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/d/dabigatran\",\n  urlKf: \"https://www.kinderformularium.nl/geneesmiddel/20152/dabigatran\",\n  linkName: \"Farmaceutisch Kompas\"\n}, {\n  title: \"edoxaban\",\n  url: \"https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/e/edoxaban\",\n  linkName: \"Farmaceutisch Kompas\"\n}, {\n  title: \"rivaroxaban\",\n  url: \"https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/r/rivaroxaban\",\n  urlKf: \"https://www.kinderformularium.nl/geneesmiddel/20651/rivaroxaban\",\n  linkName: \"Farmaceutisch Kompas\"\n}];\nvar _frontmatter = {\n  \"title\": \"Overzicht\",\n  \"metaTitle\": \"Overzicht DOACs\",\n  \"metaDescription\": \"Een overzicht van DOACs\",\n  \"date\": \"22-07-2022\",\n  \"parent\": \"Voorschrijven en follow-up / DOAC\",\n  \"type\": \"\",\n  \"previousUrl\": \"/voorschrijven-en-follow-up/algemene-informatie\",\n  \"previousText\": \"Voorschrijven en follow-up  / Algemene informatie\",\n  \"nextUrl\": \"/voorschrijven-en-follow-up/doac/follow-up-controles\",\n  \"nextText\": \"DOAC / Follow-up controles\"\n};\n\nvar makeShortcode = function makeShortcode(name) {\n  return function MDXDefaultShortcode(props) {\n    console.warn(\"Component \" + name + \" was not imported, exported, or provided by MDXProvider as global scope\");\n    return mdx(\"div\", props);\n  };\n};\n\nvar Divider = makeShortcode(\"Divider\");\nvar Alert = makeShortcode(\"Alert\");\nvar List = makeShortcode(\"List\");\nvar ListItem = makeShortcode(\"ListItem\");\nvar ContentLinkExternalFk = makeShortcode(\"ContentLinkExternalFk\");\nvar ContentLinkExternalKf = makeShortcode(\"ContentLinkExternalKf\");\nvar ListItemMeta = makeShortcode(\"ListItemMeta\");\nvar layoutProps = {\n  listDOAC: listDOAC,\n  _frontmatter: _frontmatter\n};\nvar MDXLayout = \"wrapper\";\nreturn function MDXContent(_ref) {\n  var components = _ref.components,\n      props = _objectWithoutProperties(_ref, _excluded);\n\n  return mdx(MDXLayout, _extends({}, layoutProps, props, {\n    components: components,\n    mdxType: \"MDXLayout\"\n  }), mdx(\"h2\", null, \"Direct werkende orale anticoagulantia (\", mdx(\"abbr\", {\n    parentName: \"h2\",\n    \"title\": \"direct werkende orale anticoagulantia\"\n  }, \"DOAC\"), \")\"), mdx(SelectDOAC, {\n    mdxType: \"SelectDOAC\"\n  }), mdx(Divider, {\n    mdxType: \"Divider\"\n  }), mdx(\"h2\", null, \"Indicaties en doseringen\"), mdx(SelectDOACIndicatie, {\n    mdxType: \"SelectDOACIndicatie\"\n  }), mdx(Divider, {\n    mdxType: \"Divider\"\n  }), mdx(Alert, {\n    message: \"De dosering wordt aangepast aan de nierfunctie (raadpleeg voor details altijd het Farmacotherapeutisch kompas)\",\n    type: \"info\",\n    showIcon: true,\n    mdxType: \"Alert\"\n  }), mdx(Alert, {\n    message: \"Dosering bij zuigelingen en kinderen zie Kinderformularium van de NKFK\",\n    type: \"info\",\n    showIcon: true,\n    mdxType: \"Alert\"\n  }), mdx(List, {\n    itemLayout: \"horizontal\",\n    size: \"large\",\n    bordered: true,\n    dataSource: listDOAC,\n    renderItem: function renderItem(item) {\n      return mdx(ListItem, {\n        key: item.title,\n        actions: [mdx(React.Fragment, null, item.url && mdx(ContentLinkExternalFk, {\n          title: item.title,\n          url: item.url,\n          mdxType: \"ContentLinkExternalFk\"\n        }), item.url && item.urlKf && mdx(Divider, {\n          type: \"vertical\",\n          mdxType: \"Divider\"\n        }), item.urlKf && mdx(ContentLinkExternalKf, {\n          title: item.title,\n          url: item.url,\n          mdxType: \"ContentLinkExternalKf\"\n        }))],\n        mdxType: \"ListItem\"\n      }, mdx(ListItemMeta, {\n        title: item.title,\n        mdxType: \"ListItemMeta\"\n      }));\n    },\n    mdxType: \"List\"\n  }));\n}\n;\nMDXContent.isMDXComponent = true;","tableOfContents":{"items":[{"url":"#direct-werkende-orale-anticoagulantia-doac","title":"Direct werkende orale anticoagulantia (DOAC)"},{"url":"#indicaties-en-doseringen","title":"Indicaties en doseringen"}]},"parent":{"relativePath":"voorschrijven-en-follow-up/doac/overzicht.mdx"},"frontmatter":{"parent":"Voorschrijven en follow-up / DOAC","date":"22-07-2022","nextUrl":"/voorschrijven-en-follow-up/doac/follow-up-controles","nextText":"DOAC / Follow-up controles","previousUrl":"/voorschrijven-en-follow-up/algemene-informatie","previousText":"Voorschrijven en follow-up  / Algemene informatie"}},"allMdx":{"edges":[{"node":{"fields":{"slug":"/afbakening","title":"Afbakening"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica","title":"Bloedingen onder antitrombotica"}}},{"node":{"fields":{"slug":"/colofon","title":"Colofon"}}},{"node":{"fields":{"slug":"/contact","title":"Contact"}}},{"node":{"fields":{"slug":"/inleiding","title":"Inleiding"}}},{"node":{"fields":{"slug":"/colofon/afkortingenlijst","title":"Afkortingenlijst"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/gezamenlijke-besluitvorming","title":"Gezamenlijke besluitvorming"}}},{"node":{"fields":{"slug":"/colofon/verantwoording","title":"Verantwoording"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/informatievoorziening","title":"Informatievoorziening"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/therapietrouw","title":"Therapietrouw"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/veelgestelde-vragen-over-doacs","title":"Veelgestelde vragen over DOACs"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/overzicht-periprocedureel-bloedingsrisico","title":"Overzicht periprocedureel bloedingsrisico"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/overzicht-trombo-embolie-risico","title":"Overzicht trombo-embolie risico"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-factor-xa-remmers-rivaroxaban-apixaban-edoxaban","title":"Beslisboom DOAC - factor Xa-remmers, Rivaroxaban, Apixaban, Edoxaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-beleid-bij-bloedingen-voor-de-huisarts","title":"Beslisboom Beleid bij bloedingen voor de huisarts"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-doac","title":"Beslisboom DOAC"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-vka","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-apixaban","title":"Beslisboom Apixaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/bloeding-onder-lmwh-ongefractioneerde-heparine","title":"Bloeding onder LMWH/ ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-rivaroxaban","title":"Beslisboom Rivaroxaban"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-prasugrel-clopidogrel-ticagrelor","title":"Beslisboom DAPT ASA en prasugrel, clopidogrel, ticagrelor"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-dipyridamol","title":"Beslisboom DAPT ASA en dipyridamol"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-monotherapie-clopidogrel-of-asa","title":"Beslisboom monotherapie Clopidogrel of ASA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/minimale-duur-onderbreken-en-herstarten-dapt","title":"Minimale duur onderbreken en herstarten DAPT"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/doac/follow-up-controles","title":"Follow-up controles"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/doac/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/lmwh/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/tar/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/tar/follow-up-controles","title":"Follow-up controles"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-edoxaban","title":"Beslisboom Edoxaban"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/vka/follow-up-controles","title":"Follow-up controles"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/vka/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-dabigatran/schematisch","title":"Beslisboom DOAC- dabigatran"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-tar/schematisch","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-vka/schematisch","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-doac/schematisch","title":"Beslisboom DOAC"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-vka/schematisch","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-apixaban/schematisch","title":"Beslisboom Apixaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-tar/schematisch","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-dabigatran/schematisch","title":"Beslisboom Dabigatran"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-rivaroxaban/schematisch","title":"Beslisboom Rivaroxaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-factor-xa-remmers-rivaroxaban-apixaban-edoxaban/schematisch","title":"Beslisboom DOAC - factor Xa-remmers, Rivaroxaban, Apixaban, Edoxaban"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-edoxaban/schematisch","title":"Beslisboom Edoxaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-beleid-bij-bloedingen-voor-de-huisarts/schematisch","title":"Beslisboom Beleid bij bloedingen voor de huisarts"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-dipyridamol/schematisch","title":"Beslisboom DAPT ASA en dipyridamol"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-monotherapie-clopidogrel-of-asa/schematisch","title":"Beslisboom monotherapie Clopidogrel of ASA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/vka/beslisboom-vka/schematisch","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-prasugrel-clopidogrel-ticagrelor/schematisch","title":"Beslisboom DAPT ASA en prasugrel, clopidogrel, ticagrelor"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/dual-antiplatelet-therapy-dapt-behandeling","title":"Dual Antiplatelet Therapy (DAPT) behandeling"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/vka/aanbevelingen-overbrugging-en-herstarten-vka","title":"Aanbevelingen overbrugging en herstarten VKA"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/lmwh/dosering-lmwh-bij-verminderde-nierfunctie","title":"Dosering LMWH bij verminderde nierfunctie"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/hoog-complexe-antistolling","title":"Hoog complexe antistolling"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/laag-complexe-antistolling","title":"Laag complexe antistolling"}}},{"node":{"fields":{"slug":"/literatuur","title":"Literatuur"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-vka","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-dabigatran","title":"Beslisboom DOAC - dabigatran"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/vka/beslisboom-vka","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/extra-opmerkingen-tandheelkundige-ingrepen","title":"Extra opmerkingen tandheelkundige ingrepen"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-dabigatran","title":"Beslisboom Dabigatran"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/veelgestelde-vragen-over-vka","title":"Veelgestelde vragen over VKA"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine/schematisch","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-tar","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine/schematisch","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-tar","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/changelog","title":"Changelog"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/","title":"Welkom!"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/extra-opmerkingen-endoscopische-ingrepen","title":"Extra opmerkingen endoscopische ingrepen"}}}]}},"pageContext":{"id":"de093293-ceef-5200-8515-5de72ce93eee"}},
    "staticQueryHashes": ["1620603387","2744294623","3578633366","3706406642","4066733661"]}